BONE MARROW STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS New Players in MSOctober 30, 2010 18:10
The copyright for all illustrations and pictures has been heeded by all authors to the best of their knowledge. If you feel your copyright has been infringed in any way or if you have any questions, do contact us by clicking on this link, please.
|Congress:||The 4th World Congress on Controversies in Neurology (CONy)|
Bone marrow or Hematopoietic stem cell transplantation (BMT, HSCT), both allogeneic and autologous, has become one of the hottest areas of clinical immunology. One of the main autoimmune diseases, in which HSCT was extensively tried during the last decade, is Multiple Sclerosis (MS). Autologous HSCT (ASCT) relies on an extensive debulking of the autoaggressive immune system, followed by the re-infusion of the patients' HSC (commonly identified as CD34+ cells). The allogeneic procedure is based on the substitution of the faulty immune system by a new healthy one, theoretically capable of eradicating the autoimmune clones by means of the classical combination of high-dose immunosuppressive therapy and a Graft versus- Autoimmunity (GVA) effect.
|Category:||Therapeutics; Inflammation; Stem Cells; Stem Cell Therapy; Neurology; Multiple Sclerosis; treatment;|
Trending Content Box
- Should recently approved antiepileptic drugs be used early in the treament of epilepsy? the answer is no. By Prof. E. Beghi
- Dimethyl Fumarate by Prof. Jacek Losy
- Complete Mesocolic Excision: a way to standardize Colon Cancer Surgery by Prof. Werner Hohenberger
- Agents targeting the mTOR-PI3K-Akt pathway by Prof. J. Tabernero
- Prostate specific membrane antigen antibody drug conjugate PSMA ADC): a phase 1 trial in castration-resistant metastatic prostate cancer by Prof. D. Petrylak
- Bone marrow stem cell transplantation in mulitple sclerosis by Prof. D. Karussis
- Secretomics of endometrial fluid for non-invasive assessment of endometrial receptivity by Prof. Nick Macklon
- The global epidemiology of syphilis and the challenges and opportunities to address maternal and congenital syphilis by Prof. F. Ndow
- Adalimumab for induction of clinical remission in moderately to severe active ulceratice colitis by Prof. W. Reinisch
- Current management of AIN3 and cancer by Prof. S. Goldstone